<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epithelial-Mesenchymal Transition is a good example of cell plasticity </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:mp ids='MP_0002006'>tumorigenesis</z:mp>, this process has been associated with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Overexpression of EZH2 has been detected in most malignant human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, including colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Herein, we provide evidence supporting the idea that oncogenic Epithelial-Mesenchymal Transition in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell models is partially controlled by epigenetic factors such as the transcription regulator EZH2 </plain></SENT>
<SENT sid="4" pm="."><plain>Evaluation of EZH2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels revealed overexpression in cell lines with metastatic traits </plain></SENT>
<SENT sid="5" pm="."><plain>Analysis of EZH2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was expanded in clinical samples of <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, and high level of EZH2 correlates with appearance of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, inhibition of ERK and AKT pathways in metastatic <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines attenuates EZH2 overexpression </plain></SENT>
<SENT sid="7" pm="."><plain>EZH2 promoter analysis illustrates presence of putative AP-1 binding sites and occupancy of transcription factors such as FRA-1 and C-JUN is demonstrated here on EZH2 promoter </plain></SENT>
<SENT sid="8" pm="."><plain>Abrogation of EZH2 expression impairs the ability of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells to move associated with anoikis in three-dimensional environment </plain></SENT>
<SENT sid="9" pm="."><plain>Integrin alpha2 was identified to be a novel EZH2 target by chromatin immunoprecipitation and short hairpin <z:chebi fb="40" ids="33697">RNA</z:chebi> analysis </plain></SENT>
<SENT sid="10" pm="."><plain>This study proposes that activation of ERK/AKT pathways and FRA1/C-JUN induce EZH2 overexpression, which results in Integrin alpha2 silencing </plain></SENT>
<SENT sid="11" pm="."><plain>Our results show how deregulation of epigenetic factors and mechanisms can affect <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell <z:hpo ids='HP_0000718'>aggressiveness</z:hpo> and propose EZH2 as a potential <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> marker and/or therapeutic target for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> treatment </plain></SENT>
</text></document>